Vyleesi (Bremelanotide) Real-World Evidence: What Registries and Post-Market Data Show

Why Real-World Evidence Matters for Vyleesi

Randomized controlled trials measure efficacy under ideal conditions. Real-world evidence (RWE) captures what happens when patients self-administer a drug at home, skip doses, or stop refilling prescriptions. For a PRN (as-needed) medication like bremelanotide, the gap between trial behavior and real-world use can be large.

Trial Conditions vs. Everyday Use

In the RECONNECT trials, participants received structured counseling, used electronic diaries, and had regular clinic visits 1. That level of support does not reflect typical clinical practice. A premenopausal woman prescribed Vyleesi by a telehealth provider may receive a 30-second medication overview and no follow-up for months. RWE helps fill that gap by tracking outcomes, adherence, and adverse events in routine care settings.

The HSDD RWE Field

HSDD itself is underdiagnosed. A U.S. Prevalence study estimated that 8.9% of women ages 18 to 44 meet HSDD diagnostic criteria, yet fewer than half have discussed low desire with a clinician 2. This diagnostic gap means the real-world population using Vyleesi may differ meaningfully from trial cohorts in baseline distress scores, comorbidities, and concurrent medications.

How Bremelanotide Works: Mechanism Recap

Bremelanotide is a synthetic cyclic peptide that activates melanocortin-4 receptors (MC4Rs) in the central nervous system. Understanding the mechanism is relevant to interpreting RWE because it explains both the drug's onset profile and its most common side effect.

Central Nervous System Pathway

MC4R activation in hypothalamic and limbic regions modulates dopaminergic and noradrenergic signaling involved in sexual arousal and desire 3. Unlike flibanserin, which requires daily dosing to shift serotonin-dopamine balance over weeks, bremelanotide acts within 45 minutes of a single injection. This on-demand pharmacology is central to real-world adherence patterns.

Why Nausea Occurs

MC4R is also expressed in the area postrema, a brainstem region that triggers nausea. In the RECONNECT pooled analysis, 40.0% of bremelanotide-treated patients reported nausea versus 1.3% on placebo 1. The nausea is dose-dependent and typically peaks within 1 to 2 hours. Repeated dosing appears to reduce nausea severity over time, a pattern sometimes called tachyphylaxis. Real-world reports from FAERS suggest nausea remains the primary reason for early discontinuation.

The RECONNECT Trials: Baseline for RWE Comparison

The Phase 3 RECONNECT program enrolled 1,247 premenopausal women with acquired, generalized HSDD across two identically designed trials. Mean age was 36 years. Participants self-administered bremelanotide 1.75 mg subcutaneously as needed before anticipated sexual activity for 24 weeks.

Key Efficacy Findings

Bremelanotide produced a statistically significant increase in desire and a decrease in distress compared to placebo. The co-primary endpoints used the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 and the Female Sexual Function Index (FSFI) desire domain 1. The mean FSFI desire-domain score increased by 0.56 points above placebo (P<0.001). Approximately 50% of bremelanotide-treated women reported a clinically meaningful improvement in sexual desire, compared to about 35% on placebo.

What Trials Could Not Tell Us

RECONNECT excluded women with uncontrolled hypertension, cardiovascular disease, or major psychiatric disorders. It also excluded women using hormonal contraceptives other than stable long-term methods. These exclusions mean the trial population was healthier and more homogeneous than the broader HSDD population. Real-world data are needed to understand how bremelanotide performs in women with these common comorbidities.

Post-Market Surveillance: FAERS and Safety Signals

The FDA Adverse Event Reporting System (FAERS) is the largest passive surveillance database for post-market drug safety in the United States. Since Vyleesi's approval, FAERS has accumulated reports that provide a rough signal of real-world tolerability.

Nausea Dominates Reports

Through the first three years post-approval, nausea and flushing accounted for the majority of FAERS submissions for bremelanotide 4. Injection-site reactions were reported less frequently than predicted by trials, possibly because experienced self-injectors tolerate minor reactions without reporting them. No new safety signals (such as cardiac events or melanocyte neoplasia) emerged that were absent from the key trials.

Blood Pressure Considerations

The bremelanotide label notes a transient mean increase of 6 mmHg systolic and 3 mmHg diastolic, peaking approximately 2 to 3 hours after injection 5. In the RECONNECT open-label extension, no sustained hypertension-related adverse events were identified over 52 weeks. FAERS data have not flagged hypertensive crises or cardiovascular events at a rate above background, though the small user base limits statistical power.

Skin Hyperpigmentation

Because melanocortin receptors regulate melanogenesis, the FDA required monitoring for focal hyperpigmentation. In RECONNECT, 1% of treated patients developed darkening of gingival tissue or facial skin. FAERS reports include scattered hyperpigmentation cases, but the overall incidence appears consistent with the labeled rate. No cases of melanoma attributable to bremelanotide have been reported 5.

Pharmacy Claims and Persistence Data

Pharmacy benefit manager (PBM) databases and claims analyses offer a different angle on real-world use: how long patients keep refilling prescriptions.

Refill Patterns

Published abstracts from AMAG Pharmaceuticals (the initial U.S. Distributor) presented at the 2020 ISSWSH annual meeting indicated that approximately 35% of women who filled a first Vyleesi prescription returned for a second fill within 90 days 6. That persistence rate is comparable to flibanserin's early refill trajectory and reflects the combined influence of cost, side effects, and perceived efficacy.

Cost as a Barrier

Vyleesi launched at a wholesale acquisition cost of approximately $900 for a carton of 8 autoinjectors. Even with copay assistance programs, out-of-pocket costs remained high for many patients. Insurance coverage varied widely. Claims data suggest that prior-authorization denials contributed to a meaningful share of non-persistence, independent of clinical response.

Real-World Dosing Frequency

Trial participants averaged 2 to 3 doses per month. Claims data suggest a similar pattern in practice: most women who persist past the first carton use 1 to 3 autoinjectors monthly. The PRN model means that low utilizers may stretch a single carton over several months, complicating traditional adherence metrics that assume fixed dosing intervals.

Observational Studies and Registry Efforts

Large-scale, prospective RWE registries specifically for bremelanotide are still maturing. Several data sources provide partial real-world pictures.

Open-Label Extension Data

The RECONNECT open-label extension followed 684 women for up to 52 additional weeks of as-needed bremelanotide 7. While not a registry in the traditional sense, this extension provides the closest approximation to long-term real-world use in a monitored population. Desire-domain scores remained stable through 12 months, and nausea rates declined from the randomized phase. Approximately 73% of women who entered the extension completed it, a figure that likely overestimates real-world persistence because study participants receive free drug and regular follow-up.

Electronic Health Record Studies

Retrospective EHR analyses from large health systems have begun to characterize the demographics and comorbidity profiles of women prescribed Vyleesi in practice. Preliminary findings suggest the real-world population skews slightly older (mean age 38 to 41) than the RECONNECT population (mean age 36) and carries higher rates of depression and anxiety. These comorbidities were partially excluded from trials, making EHR data valuable for understanding effectiveness in broader populations.

ISSWSH and NAMS Contributions

The International Society for the Study of Women's Sexual Health (ISSWSH) and the North American Menopause Society (NAMS) have published position statements supporting RWE collection for HSDD therapies 8. Both organizations emphasize that prospective registries should capture patient-reported outcomes alongside claims data, because desire is subjective and poorly captured by ICD codes alone.

Comparing RWE Across HSDD Therapies

Bremelanotide is one of only two FDA-approved pharmacotherapies for HSDD. Comparing its real-world trajectory against flibanserin provides context.

Flibanserin as a Benchmark

Flibanserin (Addyi), approved in 2015, has a longer post-market record. Claims analyses showed that fewer than 10% of initial prescriptions led to sustained use at 12 months 9. Daily dosing burden, alcohol restrictions, and modest efficacy all contributed. Bremelanotide's PRN dosing model eliminates the daily-pill fatigue, but introduces injection-related barriers (needle aversion, refrigeration, injection-site reactions). Real-world persistence for both drugs remains lower than for most chronic-disease medications.

Testosterone Off-Label Use

Outside the U.S., transdermal testosterone for HSDD in postmenopausal women has accumulated more RWE than either FDA-approved agent. The Global Consensus Position Statement on testosterone therapy (2019) cited registry data from Australia and the U.K. Showing sustained benefit over 24 months with low adverse-event rates 10. Bremelanotide's RWE base has not yet reached that level of maturity for premenopausal populations.

Gaps in Current Real-World Data

Despite accumulating post-market experience, several gaps remain in the bremelanotide RWE field.

Diverse Populations

RECONNECT enrolled a population that was 82% white and predominantly college-educated. FAERS and claims databases do not reliably capture race, ethnicity, or socioeconomic status. Whether bremelanotide's efficacy and tolerability generalize across diverse populations is unknown. ISSWSH has called for RWE collection that intentionally oversamples underrepresented groups.

Long-Term Safety Beyond 18 Months

The open-label extension provides up to 76 weeks of exposure data. Beyond that horizon, safety data are limited to FAERS passive surveillance. MC4R agonism does not have a theoretical link to carcinogenesis, but long-term melanocyte stimulation warrants continued observation. No registry has reported outcomes beyond two years of intermittent use.

Partner and Relationship Outcomes

Trials measured individual desire and distress scores. Real-world HSDD management occurs within relationships, and partner satisfaction, relationship quality, and sexual concordance are unmeasured in existing RWE. Validated instruments like the Dyadic Adjustment Scale have not been incorporated into bremelanotide registries.

Head-to-Head Comparisons

No randomized trial or observational study has directly compared bremelanotide to flibanserin. Claims data can provide indirect comparisons of persistence and switching patterns, but confounding by indication limits causal inference. A pragmatic comparative-effectiveness trial would fill a significant evidence gap.

Clinical Takeaways from Available RWE

The evidence that exists supports several practical conclusions for prescribers.

Setting Patient Expectations on Nausea

Counsel patients that nausea affects roughly 4 in 10 women on their first dose but tends to diminish with repeated use. Suggesting an antiemetic (ondansetron 4 mg orally, 30 minutes before the injection) is an off-label strategy reported anecdotally in clinical practice, though no RWE dataset has formally evaluated this approach.

Monitoring Blood Pressure

Check blood pressure at baseline before prescribing. The label advises against use in women with uncontrolled hypertension or known cardiovascular disease. For women with well-controlled hypertension, home blood-pressure monitoring after the first two doses can identify outliers.

Reassessing at 8 Weeks

If a patient has used at least 4 to 6 doses over 8 weeks without meaningful improvement in desire or distress, reassess the diagnosis and discuss alternative approaches. The RECONNECT protocol defined response at 24 weeks, but real-world prescribers report that most responders notice a difference within the first month.

Documenting for Future Registries

Record baseline FSFI or FSDS scores and reassess at follow-up visits. Even if no formal registry is available, structured documentation in the EHR contributes to retrospective RWE when health systems query their databases.

The bremelanotide post-market period is still relatively early. Women considering Vyleesi should know that safety data from FAERS and open-label extensions remain consistent with the RECONNECT profile, but prospective registry results with 3 to 5 year follow-up are needed before long-term confidence intervals narrow. Prescribers should document outcomes systematically, because the next wave of bremelanotide RWE will come from the clinics generating it now.